3,4-dihydroxy-naphthalene-1-sulfonic acid | 16223-99-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3,4-dihydroxy-naphthalene-1-sulfonic acid
• 英文别名: 1,2-dihydroxynaphthalene-4-sulfonic acid；3,4-Dihydroxy-naphthalin-1-sulfonsaeure；1,2-dihydroxy-4-naphthalene sulphonic acid；1,2-Dihydroxy-naphtalin-4-sulfonsaeure；3,4-Dihydroxynaphthalene-1-sulfonic acid
• CAS: 16223-99-7
• 化学式: C₁₀H₈O₅S
• 分子量: 240.237
• InChiKey: YBEQJFZNOBLHMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4-dihydroxy-naphthalene-1-sulfonic acid 在 air 作用下， 生成 2-羟基-1,4-萘醌
  参考文献：
  名称：

  DE70867

  摘要：

  公开号：
• 作为产物：
  描述：

  1,2-萘醌 在 sodium hydrogensulfite 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以79%的产率得到3,4-dihydroxy-naphthalene-1-sulfonic acid
  参考文献：
  名称：

  开发一种用于将亚硫酸氢盐添加到亲电子烯烃中的温和程序

  摘要：

  由于所需条件的苛刻性，活化烯烃的磺酰化是重要但尚未探索的反应。我们已经确定了允许烯烃与等摩尔量的亚硫酸氢盐在室温下反应的方法。

  DOI：

  10.1002/adsc.201000543

文献信息

• [EN] A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE COMPOSÉS CONTENANT DU SOUFRE
  申请人：ROYAL COLLEGE OF SURGEONS IE

  公开号：WO2010066450A1

  公开（公告）日：2010-06-17

  The invention provides a method for preparing sulfur-containing compounds, the method comprising reacting a donor compound comprising at least one sulfur having at least one lone pair of electrons, with an acceptor compound; wherein the reaction occurs in the presence of an amine, optionally an amine catalyst, capable of activating the sulfur having at least one lone pair of electrons; and wherein the reaction occurs via the formation of an transient intermediate species, optionally a transient intermediate species, between the amine, optionally the amine catalyst and the donor compound; and wherein the donor compound is selected from the group consisting of a sulfurous acid, a sulfenic acid and a sulfinic acid or a salt, ester or amide of a sulfurous acid, a sulfenic acid and a sulfinic acid. The invention also provides sulfur-containing compounds of the formula: wherein R is selected from: (a) 1 -(4-Nitro-phenyl)-3-oxo-3-phenyl-propane; (b) 2-(3-Methyl-4-nitro-isoxazol-5-yl)-1 -phenyl-ethane; (c) 1-(4-Methoxy-phenyl)-2-(3-methyl-4-nitro-isoxazol-5-yl)-ethane; (d) 2-(3-Methyl-4-nitro-isoxazol-5-yl)-1-(4-nitro-phenyl)-ethane; (e) 1-(4-Fluoro-phenyl)-2-(3-methyl-4-nitro-isoxazol-5-yl)-ethane; (f) 1 -(4-Chloro-phenyl)-2-(3-methyl-4-nitro-isoxazol-5-yl)-ethane; and (g) 3-Oxo-cyclohexane. Finally, the invention provides use of chiral sulfur-containing compounds obtainable by the above-mentioned method or chiral sulfur-containing compounds as mentioned above for the resolution of racemic mixtures of amines.

  该发明提供了一种制备含硫化合物的方法，该方法包括将包含至少一个硫原子且至少一个孤对电子的给体化合物与受体化合物反应；其中，在胺的存在下进行反应，可选地，在能够激活至少一个硫原子具有至少一个孤对电子的胺的存在下进行反应；反应通过形成瞬态中间体物种进行，可选地，通过胺、可选地胺催化剂和给体化合物之间的瞬态中间体物种进行反应；给体化合物选自包括亚硫酸、亚硫酸和亚砜酸或亚硫酸、亚硫酸和亚砜酸的盐、酯或酰胺的群；该发明还提供了符合以下公式的含硫化合物：其中R选自：(a) 1-(4-硝基苯基)-3-氧代-3-苯基-丙烷；(b) 2-(3-甲基-4-硝基异噁唑-5-基)-1-苯基-乙烷；(c) 1-(4-甲氧基苯基)-2-(3-甲基-4-硝基异噁唑-5-基)-乙烷；(d) 2-(3-甲基-4-硝基异噁唑-5-基)-1-(4-硝基苯基)-乙烷；(e) 1-(4-氟苯基)-2-(3-甲基-4-硝基异噁唑-5-基)-乙烷；(f) 1-(4-氯苯基)-2-(3-甲基-4-硝基异噁唑-5-基)-乙烷；和(g) 3-氧代环己烷。最后，该发明提供了通过上述方法获得的手性含硫化合物或上述提到的手性含硫化合物用于分离胺的外消旋混合物。
• Cephalosporin derivatives
  申请人：ICI Pharma

  公开号：US05017569A1

  公开（公告）日：1991-05-21

  Cephalosporin compounds having a 3-position substituent of the formula (I) are described: --CH.sub.2 --Y--Q (I) wherein Y is a linking group --NR.sup.4 CO--Y'--, --NR.sup.4 SO.sub.2 --Y'--, --OCO--Y;-- or --SCO--Y'-- wherein R.sup.4 is hydrogen, various optionally substituted alkyl groups or alkenyl and Y' is a bond or various optionally substituted alkylene or alkenylene groups; and Q is a benzene ring (optionally fused to a further benzene ring so forming a naphthyl group or optionally fused to a 5 or 6 membered heterocyclic aromatic group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur), said benzene ring (or in the case of naphthyl either benzene ring) being substituted by groups R.sup.1 and R.sup.2 which are ortho with respect to one another, wherein R.sup.1 is hydroxy or an in vivo hydrolyzable ester thereof and R.sup.2 is hydroxy, an in vivo hydrolyzable ester thereof, carboxy, sulpho, hydroxymethyl, methanesulphonamido or ureido; or Q is a group of the formula (II) or (III): ##STR1## wherein M is oxygen or a group NR.sup.3 wherein R.sup.3 is hydrogen or C.sub.1-4 alkyl; ring Q being further optionally substituted. The use of such compounds as antibacterial agents is described as are processes for their preparation and intermediates therefor.

  头孢菌素化合物具有式(I)的3位取代基，描述如下：--CH.sub.2 --Y--Q (I)其中Y是连接基--NR.sup.4 CO--Y'--，--NR.sup.4 SO.sub.2 --Y'--，--OCO--Y;--或--SCO--Y'--其中R.sup.4是氢，各种可选择取代的烷基或烯基，Y'是键或各种可选择取代的亚烷基或烯基基团；Q是苯环（可选择与另一苯环融合形成萘基或可选择与含有1、2或3个异原子（从氮、氧和硫中选择）的5或6成员杂环芳基团融合），所述苯环（或在萘基的情况下是任一苯环）被基团R.sup.1和R.sup.2取代，这些基团与彼此相对位，其中R.sup.1是羟基或其体内可水解酯，R.sup.2是羟基，其体内可水解酯，羧基，磺酸基，羟甲基，甲磺酰胺基或脲基；或Q是式(II)或(III)的基团：##STR1##其中M是氧或基团NR.sup.3，其中R.sup.3是氢或C.sub.1-4烷基；环Q进一步可选择取代。描述了这类化合物作为抗菌剂的用途，以及它们的制备方法和中间体。
• Cephalosporin compounds, process for their preparation and pharmaceutical compositions containing them
  申请人：ZENECA Pharma S.A.

  公开号：EP0267733A2

  公开（公告）日：1988-05-18

  ephalosporin compounds having a 3-position substituent of the formula (I) are described: wherein Y is a linking group -NR4CO-Y'-, -NR4SOrY'-, -OCO-Y;-or -SCO-Y'-wherein R4 is hydrogen, various optionally substituted alkyl groups or alkenyl and Y' is a bond or various optionally substituted alkylene or alkenylene groups; and Q is a benzene ring (optionally fused to a further benzene ring so forming a naphthyl group or optionally fused to a 5 or 6 membered heterocyclic aromatic group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur), said benzene ring (or in the case of naphthyl either benzene ring) being substituted by groups R1 and R2 which are ortho with respect to one another, wherein R' is hydroxy or an in vivo hydrolysable ester thereof and R2 is hydroxy, an in vivo hydrolysable ester thereof, carboxy, sulpho, hydroxymethyl, methanesulphonamido or ureido; or Q is a group of the formula (II) or (III): wherein M is oxygen or a group NR3 wherein R3 is hydrogen or C1-4 alkyl; ring Q being further optionally substituted. The use of such compounds as antibacterial agents is described as are processes for their preparation and intermediates therefor.

  描述了具有式（I）的 3 位取代基的头孢菌素化合物： 其中 Y 是连接基团-NR4CO-Y'-、-NR4SOrY'-、-OCO-Y;-或-SCO-Y'-，其中 R4 是氢、各种任选取代的烷基或烯基，Y'是键或各种任选取代的亚烷基或烯基；Q 是苯环（可选择与另一个苯环融合形成萘基，或可选择与含有 1、2 或 3 个选自氮、氧和硫的杂原子的 5 或 6 位杂环芳基融合）、所述苯环（或萘基中的任一苯环）被彼此正交的基团 R1 和 R2 取代，其中 R' 为羟基或其体内可水解的酯，R2 为羟基、其体内可水解的酯、羧基、磺基、羟甲基、甲磺酰胺基或脲基；或 Q 是式 (II) 或 (III) 的基团： 其中 M 是氧或基团 NR3，其中 R3 是氢或 C1-4 烷基；环 Q 可进一步被任选取代。 本文介绍了此类化合物作为抗菌剂的用途，以及其制备工艺和中间体。
• Ink for inkjet printing, lithographic printing plate using it and method for making such plate
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP1693427A2

  公开（公告）日：2006-08-23

  The present invention provides an ink for use in inkjet printing which can be cured by irradiation of radiant ray, characterized in that said ink for use in inkjet printing contains at least a colorant, a polymerizable compound and a photopolymerization initiator, further comprising a compound capable of forming a complex with a metal, as well as a method for making a lithographic printing plate that doesn't need a development process using said ink, and such plate can solve the foregoing problem. The ink of the present invention for use in inkjet printing has an excellent adhesion between the ink cured by irradiation of radiant ray and a printing medium, as well as a lithographic printing plate using it and a method for making such plate.

  本发明提供了一种可通过辐射线照射固化的喷墨印刷用墨水，其特征在于所述喷墨印刷用墨水至少含有着色剂、可聚合化合物和光聚合引发剂，还包括一种能够与金属形成络合物的化合物，以及一种使用所述墨水制作无需显影工序的平版印刷版的方法，这种版可以解决上述问题。本发明用于喷墨印刷的墨水在通过辐射线照射固化的墨水和印刷介质之间具有极佳的附着力，还包括使用本发明墨水的平版印刷板和制作这种印版的方法。
• Fieser, Journal of the American Chemical Society, 1926, vol. 48, p. 1101
  作者：Fieser

  DOI：——

  日期：——